首页|康艾注射液联合化疗及贝伐珠单抗对晚期结直肠癌患者疗效及生存的影响

康艾注射液联合化疗及贝伐珠单抗对晚期结直肠癌患者疗效及生存的影响

扫码查看
目的:探讨康艾注射液联合化疗及贝伐珠单抗对晚期结直肠癌(mCRC)患者疗效及生存的影响.方法:回顾性分析2018年6月~2021年12月芜湖市第一人民医院诊治的mCRC患者68例,分为A、B两组,A组34例给予康艾注射液联合CA-PEOX 方案(奥沙利铂+卡培他滨)及贝伐珠单抗一线方案治疗,B组34例予化疗及贝伐珠单抗一线方案治疗(方案同A组).5周期治疗后,两组肿瘤未进展的患者,改为卡培他滨维持治疗至疾病进展.比较两组患者的疗效、血清肿瘤标志物的变化,采用生存分析比较两组患者的中位无进展生存期(mPFS).结果:A组客观缓解率(67.6%)高于B组(41.2%)(P<0.05).A组和B组5周期治疗后的CEA及CA199水平较治疗前均下降(P<0.001),且A组治疗前后的CEA及CA199水平下降幅度均高于B组(P<0.05).A组的mPFS长于B组(P<0.05),两组病人骨髓抑制、恶心呕吐等不良反应发生率差异均无统计学意义(P>0.05).结论:与CAPEOX方案联合贝伐珠单抗相比,mCRC患者行康艾注射液联合CAPEOX方案及贝伐珠单抗治疗,可以提高临床疗效、降低血清肿瘤标志物水平和延长mPFS,且未增加不良反应.
Effect of Kang'ai injection plus chemotherapy and bevacizumab on clinical efficacy and survival in advanced colorectal cancer
Objective:To observe the effect of Kang'ai injection combined with chemotherapy and bevacizumab on the clinical efficacy and survival in the treatment of patients with advanced colorectal cancer.Methods:Retrospective analysis was conducted in 68 patients of advanced colorectal cancer treated in our hospital between June 2018 and December 2021.The patients were divided into group A(n=34),treated with Kang'ai injection combined with CAPEOX and bevacizumab as the first-line regimen,and group B(n=34),treated with CAPEOX and bevacizumab as the first-line therapy.After 5 cycles of medication,patients in the two groups without progressive disease were given capecitabine maintenance treatment until progressive disease.Then the two groups were observed and compared regarding the curative efficacy,changes of tumor markers,and median progression free survival(mPFS).Results:The objective response rate(ORR)was significantly higher in group A than in group B(67.6%vs.41.2%,P<0.05).The levels of CEA and CA199 were notably decreased in both groups after 5 cycles of treatment compared to pre-medication(P<0.001),and the decrease was dominant in group A(P<0.05).Patients in group A had longer mPFS than those in group B(P<0.05),yet there was no significant difference in the incidence of adverse reactions,including nausea,vomiting and bone marrow suppression between the two groups(P>0.05).Conclusion:Compared with CAPEOX plus bevacizumab regimen,Kang'ai injection combined with chemotherapy and bevacizumab can effectively boost the curative efficacy,inhibit CEA and CA199 levels and improve mPFS,without adding adverse response in the treatment of patients with advanced colorectal cancer.

Kang'ai injectionchemotherapyadvanced colorectal cancerbevacizumab

古爱虎、杨雪、许亚丽、怀建国

展开 >

芜湖市第一人民医院肿瘤内科,安徽 芜湖 241000

芜湖市第一人民医院病理科,安徽 芜湖 241000

康艾注射液 化疗 晚期结直肠癌 贝伐珠单抗

芜湖市科技计划

2022jc78

2024

皖南医学院学报
皖南医学院

皖南医学院学报

CSTPCD
影响因子:0.695
ISSN:1002-0217
年,卷(期):2024.43(1)
  • 17